IRS Ruling On Deductibility Of 23andMe Genetic Test Will Increase Patient Access, Firm Says

A new ruling by the US Internal Revenue Service allowing purchases of 23andMe Inc.’s genetic health test kit with tax-deductible flexible spending and health savings accounts should increase access to the product, the firm said on 23 July.

Kiev, Ukraine - 17 October 2018: 23andMe personal genetic test saliva collection kit, with tube, box and instructions. Illustrative editorial. - Image
Purchase of the health care portions of 23andMe's genetic test kit are now tax deductible, according to the IRS

Patients who buy and use 23andMe’s kit – which is used, in part, by consumers to identify their genetic risk for certain diseases and to better manage their health – will be able to deduct the medical portion of the test kit, the Internal Revenue Service (IRS) said in a ruling released 22 July.

The deduction eligibility is applicable to the 2019 tax year, and years following, according to the IRS ruling.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

June 2025: A Bumper Month For New EU Medtech Documents And Initiatives

 

The rate at which new documents to support the implementation of EU medtech regulations are issued has slowed of late; but June bucked the trend, with a flurry of activity.

NICE’s Rules-Based Pathway And Innovator Passports Get Go-Ahead In UK NHS 10-Year Plan

 
• By 

The NHS 10-Year Plan officially released on July 3 will crystalize NICE’s Rules-Based Pathway – a new concept for medtech evaluation that will come with a guarantee of funding – but only for a select number of products. Government to also introduce “innovator passport” to speed innovation into NHS.

New Draft Guidance Clarifies FDA’s UDI Rules For Combination Products

 
• By 

The FDA has released draft guidance clarifying UDI rules for drug- and device-led combination products. The document specifies labeling requirements and makes recommendations to reduce confusion between UDIs and NDCs. Comments are being accepted until Sept. 24.